CA2913318C - Binding molecules that bind human complement factor c2 and uses thereof - Google Patents

Binding molecules that bind human complement factor c2 and uses thereof Download PDF

Info

Publication number
CA2913318C
CA2913318C CA2913318A CA2913318A CA2913318C CA 2913318 C CA2913318 C CA 2913318C CA 2913318 A CA2913318 A CA 2913318A CA 2913318 A CA2913318 A CA 2913318A CA 2913318 C CA2913318 C CA 2913318C
Authority
CA
Canada
Prior art keywords
seq
binding molecule
amino acid
antibody
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2913318A
Other languages
English (en)
French (fr)
Other versions
CA2913318A1 (en
Inventor
Cornelis Erik Hack
Cafer YILDIZ
Louis Boon
Petrus Johannes Simons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BROTEIO PHARMA BV
Original Assignee
BROTEIO PHARMA BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by BROTEIO PHARMA BV filed Critical BROTEIO PHARMA BV
Publication of CA2913318A1 publication Critical patent/CA2913318A1/en
Application granted granted Critical
Publication of CA2913318C publication Critical patent/CA2913318C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2913318A 2013-05-23 2014-05-22 Binding molecules that bind human complement factor c2 and uses thereof Active CA2913318C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13168941 2013-05-23
EP13168941.6 2013-05-23
PCT/NL2014/050327 WO2014189378A1 (en) 2013-05-23 2014-05-22 Binding molecules that bind human complement factor c2 and uses thereof

Publications (2)

Publication Number Publication Date
CA2913318A1 CA2913318A1 (en) 2014-11-27
CA2913318C true CA2913318C (en) 2024-03-26

Family

ID=48485015

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2913318A Active CA2913318C (en) 2013-05-23 2014-05-22 Binding molecules that bind human complement factor c2 and uses thereof

Country Status (14)

Country Link
US (2) US9944717B2 (enExample)
EP (2) EP2999714B1 (enExample)
JP (3) JP2016520313A (enExample)
CN (1) CN105492461B (enExample)
AU (1) AU2014269193C1 (enExample)
CA (1) CA2913318C (enExample)
DK (2) DK2999714T3 (enExample)
ES (2) ES2904709T3 (enExample)
HU (2) HUE057858T2 (enExample)
LT (2) LT2999714T (enExample)
MX (1) MX366046B (enExample)
PL (2) PL2999714T3 (enExample)
PT (2) PT3725803T (enExample)
WO (1) WO2014189378A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2914291T3 (da) 2012-11-02 2022-05-16 Bioverativ Usa Inc Anti-komplement-c1s-antistoffer og anvendelser deraf
ES2904709T3 (es) * 2013-05-23 2022-04-05 Broteio Pharma B V Moléculas de unión que se unen al factor C2B del complemento humano y usos de las mismas
CN110300520B (zh) * 2016-10-12 2022-10-04 美国比奥维拉迪维股份有限公司 抗C1s抗体及其使用方法
CN113260375B (zh) * 2018-12-13 2024-10-01 阿尔金克斯有限公司 针对人补体因子C2b的抗体及使用方法
GB2584105B (en) 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy
AU2020330307A1 (en) * 2019-08-12 2022-03-17 CSL Innovation Pty Ltd Complement C2 binding proteins and uses thereof
CA3237883A1 (en) * 2022-01-29 2023-08-03 Kira Pharmaceuticals (Suzhou) Ltd. Anti-c2 antibodies and uses thereof
GB202407051D0 (en) 2024-05-17 2024-07-03 argenx BV Methods of treating osteoarthritis pain
WO2025257157A1 (en) 2024-06-10 2025-12-18 argenx BV Treatment or prevention of ischemia reperfusion injury in organ tranplantation
WO2025260123A1 (en) * 2024-06-17 2025-12-26 CSL Innovation Pty Ltd Anti-c2 antibodies and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6998468B2 (en) 2000-03-23 2006-02-14 Tanox, Inc. Anti-C2/C2a inhibitors of complement activation
ES2904709T3 (es) * 2013-05-23 2022-04-05 Broteio Pharma B V Moléculas de unión que se unen al factor C2B del complemento humano y usos de las mismas

Also Published As

Publication number Publication date
PL3725803T3 (pl) 2022-04-04
MX2015016120A (es) 2016-10-28
AU2014269193A1 (en) 2015-12-17
ES2784616T3 (es) 2020-09-29
JP2016520313A (ja) 2016-07-14
PT2999714T (pt) 2020-04-30
US10717785B2 (en) 2020-07-21
US9944717B2 (en) 2018-04-17
LT3725803T (lt) 2022-03-10
AU2014269193B2 (en) 2019-08-15
EP3725803B1 (en) 2021-12-15
JP2020007318A (ja) 2020-01-16
MX366046B (es) 2019-06-26
JP2023002684A (ja) 2023-01-10
CN105492461A (zh) 2016-04-13
AU2014269193C1 (en) 2020-02-20
CN105492461B (zh) 2019-11-26
JP7414929B2 (ja) 2024-01-16
PL2999714T3 (pl) 2020-10-19
US20160108134A1 (en) 2016-04-21
HUE057858T2 (hu) 2022-06-28
CA2913318A1 (en) 2014-11-27
PT3725803T (pt) 2021-12-24
HUE049769T2 (hu) 2020-10-28
LT2999714T (lt) 2020-07-10
WO2014189378A1 (en) 2014-11-27
EP2999714A1 (en) 2016-03-30
EP2999714B1 (en) 2020-04-01
DK3725803T3 (da) 2022-03-07
DK2999714T3 (da) 2020-06-02
US20180319895A1 (en) 2018-11-08
HK1223385A1 (zh) 2017-07-28
ES2904709T3 (es) 2022-04-05
JP7163254B2 (ja) 2022-10-31
EP3725803A1 (en) 2020-10-21

Similar Documents

Publication Publication Date Title
US10717785B2 (en) Binding molecules that bind human complement factor C2 and uses thereof
JP2024170616A (ja) Ｍａｓｐ－２依存性の補体活性化を阻害するための組成物
EP1625166B1 (en) Antibodies to masp-2
US11066473B2 (en) Galectin-10 antibodies
JP6783754B2 (ja) 組織因子経路インヒビター（１〜１６１）上の２つのエピトープに結合する能力がある抗体
CN110475570B (zh) 抗人膜联蛋白a1抗体
KR20140019375A (ko) 인간 조직 인자 항체 및 이의 용도
JP2021510523A (ja) Ｈ因子増強抗体及びその使用
WO2018228406A1 (zh) Pcsk9抗体、其抗原结合片段及其医药用途
CN105473619B (zh) 能够引起促凝血活性的识别组织因子途径抑制剂的n-末端部分的抗体
JP7754841B2 (ja) ヒト化抗ヒトｃｄ８９抗体及びその使用
HK1223385B (zh) 结合人类补体因子c2的结合分子及其应用
RU2810094C2 (ru) Прокоагулянтные антитела
EA051993B1 (ru) Гуманизированные антитела к cd89 человека и варианты их применения
EA047651B1 (ru) Антитела против галектина-10
TW201335184A (zh) 人類組織因子抗體及其用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181115

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250513

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250513